Expertise in
10
conditions

Dr. Juan Cuevas

Hematology | Oncology
Saint Louis Cancer Care, Llp
3440 De Paul Ln Ste 201, 
Bridgeton, MO 
Accepting New Patients
Expertise in
10
conditions
Saint Louis Cancer Care, Llp
3440 De Paul Ln Ste 201, 
Bridgeton, MO 

Overview

Juan Cuevas is a Hematologist and an Oncologist practicing medicine in Bridgeton, Missouri.

Dr. Cuevas is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Pleuropulmonary Blastoma, and HER-2 Positive Breast Cancer.

Dr. Cuevas is board certified in Missouri Dept Of Health/Narcotics&Dangerous Drugs , Missouri State Board Of Registration, American Board Of Internal Medicine/Medical Oncology , and Drug Enforcement Administration . He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 8 clinical trials. Dr. Cuevas is currently accepting new patients.

Graduate Institution

Columbia School Of Medicine - Bogota

Residency

Washington University - Barnes-Jewish Hospital

Specialties

Hematology
Oncology

Licenses

Internal Medicine in MO

Board Certifications

Missouri Dept Of Health/Narcotics&Dangerous Drugs
Missouri State Board Of Registration
American Board Of Internal Medicine/Medical Oncology
Drug Enforcement Administration

Hospital Affiliations

Mercy Hospital St Louis
Ssm St Joseph Health Center
Mercy Hospital South
Ssm Health Depaul Hospital St Louis
St Lukes Hospital
SSM Health DePaul Hospital - St. Louis
SSM Health St. Clare Hospital - Fenton

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Saint Louis Cancer Care, Llp
3440 De Paul Ln Ste 201, Bridgeton, MO 63044
Other Locations
226 S. Woods Mill Road, Suite 45 West, Chesterfield, MO 63017

Additional Areas of Focus

Dr. Cuevas has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)
A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)
Enrollment Status: Completed
Publish Date: August 21, 2026
Intervention Type: Drug
Study Drugs: Tepotinib, Osimertinib
Study Phase: Phase 2
A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
Enrollment Status: Active_not_recruiting
Publish Date: July 14, 2026
Intervention Type: Drug
Study Drug: Tepotinib
Study Phase: Phase 2
Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (SCLC)
Enrollment Status: Completed
Publish Date: September 25, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Carboplatin, Etoposide, Atezolizumab
Study Phase: Phase 2
PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
Enrollment Status: Terminated
Publish Date: November 26, 2024
Intervention Type: Drug
Study Drug: Trilaciclib
Study Phase: Phase 3
A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib Versus Placebo in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated With Docetaxel in the 2nd/3rd Line Setting (PRESERVE 4)
A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib Versus Placebo in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated With Docetaxel in the 2nd/3rd Line Setting (PRESERVE 4)
Enrollment Status: Terminated
Publish Date: April 14, 2023
Intervention Type: Drug
Study Drugs: Trilaciclib, Docetaxel
Study Phase: Phase 2
Role of Circulating Tumor DNA (ctDNA) From LIquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation
Role of Circulating Tumor DNA (ctDNA) From LIquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation
Enrollment Status: Terminated
Publish Date: November 19, 2020
Intervention Type: Other
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

1 Total Publications

Measures of functional status in older patients treated with palbociclib for advanced breast cancer.
Measures of functional status in older patients treated with palbociclib for advanced breast cancer.
Journal: Journal of geriatric oncology
Published: March 23, 2023
Similar Doctors
Expertise in
5
conditions
Dr. Melanie E. Fields
Hematology | Oncology
Expertise in
5
conditions
Dr. Melanie E. Fields
Hematology | Oncology
Referral may be required

St. Louis Children's Hospital

1 Childrens Pl, 
Saint Louis, MO 
 (13.0 miles away)
314-454-6018
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Melanie Fields is a Hematologist and an Oncologist practicing medicine in Saint Louis, Missouri. Dr. Fields is highly rated in 5 conditions, according to our data. Her clinical expertise encompasses Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, and Hemolytic Anemia. Dr. Fields is currently accepting new patients.

Expertise in
29
conditions
Dr. Douglas Adkins
Hematology | Oncology
Expertise in
29
conditions
Dr. Douglas Adkins
Hematology | Oncology
Referral may be required

Washington University School Of Medicine

660 S Euclid Ave, 
Saint Louis, MO 
 (13.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Douglas Adkins is a Hematologist and an Oncologist practicing medicine in Saint Louis, Missouri. Dr. Adkins is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Head and Neck Squamous Cell Carcinoma (HNSCC), Laryngeal Cancer, Throat Cancer, Bone Tumor, and Gastrostomy. Dr. Adkins is currently accepting new patients.

Expertise in
31
conditions
Dr. Armin Ghobadi
Hematology | Oncology
Expertise in
31
conditions
Dr. Armin Ghobadi
Hematology | Oncology
Referral may be required

Washington University

4500 Forest Park Ave, 
Saint Louis, MO 
 (13.5 miles away)
314-454-8304
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Armin Ghobadi is a Hematologist and an Oncologist practicing medicine in Saint Louis, Missouri. Dr. Ghobadi is highly rated in 31 conditions, according to our data. His clinical expertise encompasses B-Cell Lymphoma, Non-Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Ghobadi is currently accepting new patients.

Frequently Asked Questions about Dr. Juan Cuevas

How do I make an appointment with Dr. Juan Cuevas?

You can book an appointment with Dr. Juan Cuevas by calling their office at 314-579-0051. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Juan Cuevas a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Juan Cuevas is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Juan Cuevas specialize in?

While Dr. Juan Cuevas is a Hematology, they have specific expertise in Breast Cancer, Paget Disease of the Breast, and Pleuropulmonary Blastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Juan Cuevas participate in research or clinical trials?

Yes. Dr. Juan Cuevas has published 1 articles and abstracts on conditions like Breast Cancer. You can view a list of Dr. Juan Cuevas's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Juan Cuevas accept my insurance?

Dr. Juan Cuevas accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 314-579-0051 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cuevas's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 85 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile